Fatty liver disease (MASLD) affects ~40% of U.S. adults and is usually silent. Dr. Casey Dean explains the FIB-4 score, lifestyle targets, and the new FDA-approved drugs for MASH.
By Dr. Casey Dean, DO · Board-Certified Family Medicine Physician (ABFM) · Published 2026-07-08 · Updated 2026-07-08
If you have never worried about your liver, here is a number worth your attention. Fatty liver disease now affects roughly 4 in 10 American adults — the most common chronic liver condition in the country — yet most people who have it have no idea. It causes few or no symptoms until it is advanced, which is what makes it dangerous. The good news: in its early stages it is one of the most reversible chronic conditions in medicine, and 2024–2025 brought the first medications ever approved to treat it. Medical terms are explained as we go.
Your liver filters your blood, processes nutrients, and stores energy. In fatty liver disease, fat droplets accumulate inside liver cells — a state doctors call hepatic steatosis (steatosis means "fatty change"). A little fat is normal; when more than about 5% of the liver's weight is fat, it becomes a medical concern.
For decades this was called nonalcoholic fatty liver disease (NAFLD). In June 2023, a global panel of liver organizations led by the American Association for the Study of Liver Diseases (AASLD) retired that name. The new umbrella term is steatotic liver disease (SLD), and the most common type is metabolic dysfunction–associated steatotic liver disease (MASLD).
Yes, especially in its early stages. Simple fatty liver and even the inflamed form (MASH) can improve or resolve with sustained weight loss, a Mediterranean-style diet, exercise, and control of blood sugar and cholesterol. Losing 7–10% of your body weight can reverse inflammation and some scarring, though advanced cirrhosis is generally not reversible — which is why early action matters.
Essentially, yes. MASLD (metabolic dysfunction–associated steatotic liver disease) is the current medical name for what used to be called NAFLD (nonalcoholic fatty liver disease). Liver societies changed the name in June 2023 to better reflect the condition's metabolic roots and to require at least one cardiometabolic risk factor for diagnosis.
Semaglutide, the drug in Wegovy and Ozempic, was FDA-approved in August 2025 (under the Wegovy brand) to treat MASH with moderate-to-advanced liver scarring — the first GLP-1 medication approved for this use. It works largely by driving weight loss and improving insulin resistance. It is approved for people with confirmed, more advanced disease, not for everyone with mild fatty liver, so a doctor's evaluation is needed.
The simplest first step is a FIB-4 score, a free calculation your doctor makes from routine blood work (age, AST, ALT, and platelet count). A low score is reassuring; an intermediate or high score points to a follow-up scan called a FibroScan or a referral to a liver specialist. This entire first step can be handled through a telehealth visit.
Yes. "Lean MASLD" occurs in people at a healthy weight. It is often driven by genetics — such as the PNPLA3 gene variant, more common in people of Hispanic ancestry — plus insulin resistance or a diet high in sugar and refined carbs. A normal weight lowers your risk but does not eliminate it, especially if fatty liver runs in your family.
Yes. Because diagnosis begins with a blood-based FIB-4 score and management centers on lifestyle and metabolic health, fatty liver disease is well-suited to telehealth. A Trinity Family Medicine physician can order your labs, calculate and interpret your risk score, and build a treatment plan from home, referring you for imaging only if needed.